Regulatory Review Time and Pharmaceutical R&D

Anna Chorniy, James Bailey, Michael Maloney and Abdulkadir Civan
Additional contact information
Abdulkadir Civan: Mercury Publication

No 6923, Working Papers from George Mason University, Mercatus Center

Abstract: We examine the responsiveness of pharmaceutical companies’ R&D strategies to the length of_x000D_ the regulatory delay. This delay is caused by U.S. Federal Drug Administration (FDA) policies in_x000D_ place regarding testing of newly developed drugs. We extend our p

Pages: Length not available.
Date: 2019-07-17
References: View references in EconPapers View complete reference list from CitEc
Citations:

Published

Downloads: (external link)
https://mercury.mercatus.org/Product/ViewFinalCopy/303 (application/pdf)
Our link check indicates that this URL is bad, the error code is: 503 Service Temporarily Unavailable

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ajw:wpaper:06923

Access Statistics for this paper

More papers in Working Papers from George Mason University, Mercatus Center Contact information at EDIRC.
Bibliographic data for series maintained by Jim Ronyak ().